The Vector Technology group utilizes the baculovirus platform for production of AAV, with a focus on vector engineering and optimization, process development, and scale-up production. The technical team at LakePharma has over 16 years of experience utilizing suspension insect cell lines and the baculovirus system for production of recombinant proteins and the AAV platform expands on those capabilities.  Extensive characterization capabilities are also available with LakePharma's assay group. 

Click here to download our Viral Vector Presentation.